+ Follow clopidogrel Tag
clopidogrel
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1666476
[Title] => As preventive, H2RA poses risk for patients on clopidogrel
[Summary] => Histamine-2 receptor antagonists may not be a viable alternative to proton pump inhibitors to prevent recurrence of bleeding peptic ulcers in clopidogrel users, a study showed.
[DatePublished] => 2017-01-29 00:00:00
[ColumnID] => 136231
[Focus] => 1
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 1355926
[Title] => Epektibo ba ang aspirin?
[Summary] => “Ako ay 42 anyos na lalaki. Nag-eehersisyo ako madalas. Nabasa ko ang tungkol sa aspirin. Bagay ba ito sa akin, Dok?”
[DatePublished] => 2014-08-10 00:00:00
[ColumnID] => 134738
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => Punto Mo
[SectionUrl] => punto-mo
[URL] =>
)
[2] => Array
(
[ArticleID] => 781003
[Title] => PPI adverse effects probably overstated, experts say
[Summary] => ‘There are interesting epidemiologic associations, but the magnitude is weak and findings are inconsistent.’
[DatePublished] => 2012-02-26 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 690567
[Title] => Clopidogrel plus aspirin cuts vascular events
[Summary] => Adding clopidogrel to aspirin therapy significantly reduces the risk of stroke and other major vascular events in patients who have atrial fibrillation and are not candidates for anticoagulation therapy with a vitamin K antagonist, according to the Population Health Research Institute in Hamilton, Ont.
[DatePublished] => 2011-05-29 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[4] => Array
(
[ArticleID] => 616171
[Title] => Sino ang dapat uminom ng aspirin
[Summary] => Ako ay 42 anyos na lalaki. Nag-eehersisyo ako madalas.
[DatePublished] => 2010-09-30 00:00:00
[ColumnID] => 134020
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => PSN Opinyon
[SectionUrl] => opinyon
[URL] =>
)
[5] => Array
(
[ArticleID] => 476128
[Title] => Local pharma firm aims to boost market foothold
[Summary] => Cebu, Philippines - Even if the industry seems to be having a slower growth rate due to the present global economic crisis, Filipino pharmaceutical company Innogen Pharma Group continues to see growth areas in the market this year.
[DatePublished] => 2009-06-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Business
[SectionUrl] => cebu-business
[URL] =>
)
[6] => Array
(
[ArticleID] => 386229
[Title] => Heart drug effective in saving lives – study
[Summary] =>
More and more people are suffering from heart attacks  and they are getting younger. Recent news of a famous young musician having a heart attack should properly warn people that heart disease does not only affect the elderly anymore.
Heart disease is the leading cause of death in the country. Department of Health data show that in 2003 alone, nearly 70,000 Filipino men and women died of heart disease.
[DatePublished] => 2007-02-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 347113
[Title] => Benefits of clopidogrel in patients with cardiovascular disease reaffirmed
[Summary] => Taking the anti-clotting medicine clopidogrel together with aspirin is beneficial to patients with known cardiovascular disease or those who suffered a heart attack or stroke, but not in patients who only have risk factors for developing a cardiovascular disease, according to the results of an international study called CHARISMA.
[DatePublished] => 2006-07-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 326517
[Title] => FDA grants priority review to new drug for acute STEMI
[Summary] => Sanofi-aventis and Bristol-Myers Squibb Co. announced recently that the US Food and Drug Administration (FDA) has accepted for review a supplemental new drug application for the antiplatelet agent clopidogrel bisulfate for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).
STEMI is a heart attack in which an artery is generally blocked completely for sufficient time to cause heart muscle damage. This blockage is caused by clot formation in the arteries, which is also known as atherothrombosis.
[DatePublished] => 2006-03-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[9] => Array
(
[ArticleID] => 286313
[Title] => The growing burden of atherothrombosis
[Summary] => Cardiovascular disease (CVD) is the leading cause of death in the Philippines. In 2001, according to the Department of Health, CVD was responsible for 28 percent of all deaths among Filipinos.
As a consequence, CVD exerts a huge and growing burden on the country’s limited resources for health services as well as on the patients and their families, many of whom pay medical services out-of-pocket.
Atherothrombosis, a progressive and life-threatening disease affecting the arteries throughout the body, is responsible for the majority of CVD cases.
[DatePublished] => 2005-07-14 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
February 22, 2007 - 12:00am
